Investigating how Interleukin-27 affects the body's response to Legionella infection
Official title: Interleukin-27 in host response to Legionella infection
Funded at Boston University Medical Campus · NIH-10871841 · Data updated 2026-11-12
This study is looking at how a substance called Interleukin-27 (IL-27) affects the immune system's response to Legionnaires' disease, a serious type of pneumonia, to help us understand how it influences inflammation and immune cell activity in the lungs during infection.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Boston University Medical Campus NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | July 1, 2023 |
| Project end | June 30, 2027 |
| Funding year | 2024 |
| Award (this year) | $689,612 |
| NIH project number | 5R01HL166588-02 |
| Project ID | NIH-10871841 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals diagnosed with Legionnaires' disease or those at high risk of developing severe pneumonia due to Legionella infection.
✕Less likely to help
Patients who do not have Legionnaires' disease or are not at risk for this specific infection may not benefit from this research.
What this research studies
This research focuses on understanding the role of Interleukin-27 (IL-27) in the immune response to Legionella infection, which causes Legionnaires' disease, a severe form of pneumonia. The study examines how IL-27 influences inflammation and the behavior of immune cells in the lungs during infection. By analyzing samples from patients and using animal models, researchers aim to uncover the mechanisms by which IL-27 affects the severity of the disease and the body's ability to fight off the infection.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic strategies that enhance the immune response against Legionella, potentially reducing mortality rates associated with Legionnaires' disease.
How similar studies have gone: Previous research has indicated that targeting cytokines like IL-27 can influence immune responses, suggesting that this approach may yield valuable insights into treating Legionnaires' disease.
Where this research is happening
-
Boston University Medical Campus
Boston, United States Active
Researchers
- Principal investigator: Bosmann, Markus — Boston University Medical Campus
- Study coordinator: Bosmann, Markus
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.